Fukuda S, Suda K, Hamada A, Oiki H, Ohara S, Ito M, et al. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study. Biomedicines. 2024;12: pubmed publisher

Jang H, Min H, Kang Y, Boo H, Kim J, Ahn J, et al. Tobacco-induced hyperglycemia promotes lung cancer progression via cancer cell-macrophage interaction through paracrine IGF2/IR/NPM1-driven PD-L1 expression. Nat Commun. 2024;15:4909 pubmed publisher

Kim J, Koh D, Lee M, Park Y, Hong S, Shin J, et al. Targeting isoforms of RON kinase (MST1R) drives antitumor efficacy. Cell Death Differ. 2023;30:2491-2507 pubmed publisher

Qin H, Chen J, Bouchekioua Bouzaghou K, Meng Y, Griera J, Jiang X, et al. Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk. J Transl Med. 2023;21:702 pubmed publisher

Ando C, Ichihara E, Nishi T, Morita A, Hara N, Takada K, et al. Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Cancer Sci. 2023;114:4343-4354 pubmed publisher

Shen B, Shi J, Zhu Z, He Z, Liu S, Shi W, et al. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma. Mol Cancer Ther. 2023;22:1479-1492 pubmed publisher

Guan J, Boren xe4 s M, Xiong J, Lai W, Palmer R, Hallberg B. IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway. Cancers (Basel). 2023;15: pubmed publisher

Meng M, Tan J, Chen H, Shi Z, Kwan H, Su T. Brevilin A exerts anti-colorectal cancer effects and potently inhibits STAT3 signaling invitro. Heliyon. 2023;9:e18488 pubmed publisher

Kuracha M, Govindarajan V, Loggie B, Tobi M, McVicker B. Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells. Int J Mol Sci. 2023;24: pubmed publisher

Lee C, Yu C, Panda S, Chen K, Liang K, Huang W, et al. Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis. J Transl Med. 2023;21:530 pubmed publisher

Siddique I, Kamble K, Gupta S, Solanki K, Bhola S, Ahsan N, et al. ARL6IP5 Ameliorates α-Synuclein Burden by Inducing Autophagy via Preventing Ubiquitination and Degradation of ATG12. Int J Mol Sci. 2023;24: pubmed publisher

Lee K, Lai T, Lee W, Chen Y, Ho K, Hung W, et al. Sustaining the Activation of EGFR Signal by Inflammatory Cytokine IL17A Prompts Cell Proliferation and EGFR-TKI Resistance in Lung Cancer. Cancers (Basel). 2023;15: pubmed publisher

Chen C, Wang S, Yang J, Huang C. Targeting Ras signaling excitability in cancer cells through combined inhibition of FAK and PI3K. bioRxiv. 2023;: pubmed publisher

Kim S, Carvajal R, Kim M, Yang H. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell Rep. 2023;42:112570 pubmed publisher

Pillay V, Shukla L, Herle P, Maciburko S, Bandara N, Reid I, et al. Radiation therapy attenuates lymphatic vessel repair by reducing VEGFR-3 signalling. Front Pharmacol. 2023;14:1152314 pubmed publisher

Paassen I, Williams J, R xed os Arceo C, Ringnalda F, Mercer K, Buhl J, et al. Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities. Oncogene. 2023;42:1661-1671 pubmed publisher

Park J, Oh K, Lee G, Bang G, Park J, Kim H, et al. Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema. Exp Mol Med. 2023;55:794-805 pubmed publisher

Tiedt R, King F, Stamm C, Niederst M, Delach S, Zumstein Mecker S, et al. Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. Cell Rep. 2023;42:112297 pubmed publisher

Lin W, Niu R, Park S, Zou Y, Kim S, Xia X, et al. IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis. Nat Commun. 2023;14:1578 pubmed publisher

Chang C, Lin B, Chen C, Nguyen N, Hsieh T, Su J, et al. Stellettin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade. Mar Drugs. 2023;21: pubmed publisher

Nakashima F, Gim xe9 nez Bastida J, Luis P, Presley S, Boer R, Chiusa M, et al. The 5-lipoxygenase/cyclooxygenase-2 cross-over metabolite, hemiketal E2, enhances VEGFR2 activation and promotes angiogenesis. J Biol Chem. 2023;299:103050 pubmed publisher

Shackleford T, Hariharan S, Vaseva A, Alagoa K, Espinoza M, Bid H, et al. Redundant Signaling as the Predominant Mechanism for Resistance to Antibodies Targeting the Type-I Insulin-Like Growth Factor Receptor in Cells Derived from Childhood Sarcoma. Mol Cancer Ther. 2023;22:539-550 pubmed publisher

Lin Z, Chung C, Liu Y, Chang C, Liu H, Liang Y, et al. EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression. elife. 2023;12: pubmed publisher

Park S, Yoon S, Choi S, Jung J, Park J, Park Y, et al. Particulate matter promotes cancer metastasis through increased HBEGF expression in macrophages. Exp Mol Med. 2022;54:1901-1912 pubmed publisher

Marques C, Po xe7 as J, Gomes C, Faria Ramos I, Reis C, Viv xe8 s R, et al. Glycosyltransferases EXTL2 and EXTL3 cellular balance dictates heparan sulfate biosynthesis and shapes gastric cancer cell motility and invasion. J Biol Chem. 2022;298:102546 pubmed publisher

Krchniakova M, Paukovcekova S, Chlapek P, Neradil J, Skoda J, Veselska R. Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells. Front Pharmacol. 2022;13:976955 pubmed publisher

Kobayashi Y, Oxnard G, Cohen E, Mahadevan N, Alessi J, Hung Y, et al. Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. Nat Commun. 2022;13:5614 pubmed publisher

Wang Y, Yu L, Hu Z, Fang Y, Shen Y, Song M, et al. Regulation of CCL2 by EZH2 affects tumor-associated macrophages polarization and infiltration in breast cancer. Cell Death Dis. 2022;13:748 pubmed publisher

Dieter S, Lovecchio D, Pataskar A, Zowada M, K xf6 rner P, Khalizieva A, et al. Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Oncogene. 2022;41:3953-3968 pubmed publisher

Ryan M, Coker O, Sorokin A, Fella K, Barnes H, Wong E, et al. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy. Cell Rep. 2022;39:110993 pubmed publisher

He X, Hikiba Y, Suzuki Y, Nakamori Y, Kanemaru Y, Sugimori M, et al. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. Sci Rep. 2022;12:8007 pubmed publisher

Gaiteiro C, Soares J, Relvas Santos M, Peixoto A, Ferreira D, Paulo P, et al. Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics. 2022;12:3150-3177 pubmed publisher

Weickhardt A, Lau D, Hodgson Garms M, Lavis A, Jenkins L, Vukelic N, et al. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. BMC Cancer. 2022;22:478 pubmed publisher

Song S, Yu Z, You Y, Liu C, Xie X, Lv H, et al. EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli. Cell Death Dis. 2022;13:351 pubmed publisher

Vannas C, Andersson L, Dolatabadi S, Ranji P, Lindén M, Jonasson E, et al. Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. Biomedicines. 2022;10: pubmed publisher

Ueda T, Ito T, Inden M, Kurita H, Yamamoto A, Hozumi I. Stem Cells From Human Exfoliated Deciduous Teeth-Conditioned Medium (SHED-CM) is a Promising Treatment for Amyotrophic Lateral Sclerosis. Front Pharmacol. 2022;13:805379 pubmed publisher

Zhi J, Yi J, Hou X, Wang W, Yang W, Hu L, et al. Targeting SHP2 sensitizes differentiated thyroid carcinoma to the MEK inhibitor. Am J Cancer Res. 2022;12:247-264 pubmed

Scherschinski L, Prem M, Kremenetskaia I, Tinhofer I, Vajkoczy P, Karbe A, et al. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma. Int J Mol Sci. 2022;23: pubmed publisher

Smith R, Odintsov I, Liu Z, Lui A, Hayashi T, Vojnic M, et al. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. Dis Model Mech. 2022;15: pubmed publisher

Patel H, Mishra R, Yacoub N, Alanazi S, Kilroy M, Garrett J. IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Cancers (Basel). 2021;13: pubmed publisher

Mannsåker T, Hoang T, Aasen S, Bjørnstad O, Parajuli H, Sundstrøm T, et al. Cabozantinib Is Effective in Melanoma Brain Metastasis Cell Lines and Affects Key Signaling Pathways. Int J Mol Sci. 2021;22: pubmed publisher

Choi J, Kim T, Jeong B, Jeon H, Jeon S, Kang M, et al. ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT). Sci Rep. 2021;11:21984 pubmed publisher

Sato T, Nakanishi H, Akao K, Okuda M, Mukai S, Kiyono T, et al. Three newly established immortalized mesothelial cell lines exhibit morphological phenotypes corresponding to malignant mesothelioma epithelioid, intermediate, and sarcomatoid types, respectively. Cancer Cell Int. 2021;21:546 pubmed publisher

Korec D, Louke D, Breitbach J, Geisler J, Husbands B, Fenger J. Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines. BMC Vet Res. 2021;17:320 pubmed publisher

Chen P, Lin C, Yang S, Chang Y. Oral submucous fibrosis stimulates invasion and epithelial-mesenchymal transition in oral squamous cell carcinoma by activating MMP-2 and IGF-IR. J Cell Mol Med. 2021;25:9814-9825 pubmed publisher

Wang Y, Liu I, Chen K, Wu H. NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck. Oncogenesis. 2021;10:59 pubmed publisher

Oh S, Noh K, Song K, Kim T. Interaction between SCP3 and JAB1 Confers Cancer Therapeutic Resistance and Stem-like Properties through EGF Expression. Int J Mol Sci. 2021;22: pubmed publisher

Nishii K, Ohashi K, Watanabe H, Makimoto G, Nakasuka T, Higo H, et al. Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression. Oncol Lett. 2021;22:639 pubmed publisher

Ebner Peking P, Krisch L, Wolf M, Hochmann S, Höög A, Vári B, et al. Self-assembly of differentiated progenitor cells facilitates spheroid human skin organoid formation and planar skin regeneration. Theranostics. 2021;11:8430-8447 pubmed publisher

Mahdal M, Neradil J, Mudry P, Paukovcekova S, Staniczkova Zambo I, Urban J, et al. New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling. Cancers (Basel). 2021;13: pubmed publisher

Harttrampf A, da Costa M, Renoult A, Daudigeos Dubus E, Geoerger B. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation. BMC Cancer. 2021;21:833 pubmed publisher

Lee S, Choi K, Bang G, Park S, Kim E, Choi J, et al. Identification of Nucleolin as a Novel AEG-1-Interacting Protein in Breast Cancer via Interactome Profiling. Cancers (Basel). 2021;13: pubmed publisher

Lee J, Chen R, Mohanakumar T, Bremner R, Mittal S, Fleming T. Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells. Onco Targets Ther. 2021;14:3813-3820 pubmed publisher

Hafner S, Schmiech M, Lang S. The Cardenolide Glycoside Acovenoside A Interferes with Epidermal Growth Factor Receptor Trafficking in Non-Small Cell Lung Cancer Cells. Front Pharmacol. 2021;12:611657 pubmed publisher

Lee H, Wang Y, Yang W, Xia W, Wei Y, Chan L, et al. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun. 2021;12:2788 pubmed publisher

Lailler C, Lamuraglia M, Racine F, Louandre C, Godin C, Chauffert B, et al. DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU). Transl Oncol. 2021;14:101110 pubmed publisher

Billing O, Holmgren Y, Nosek D, Hedman H, Hemmingsson O. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. Oncogene. 2021;40:3707-3718 pubmed publisher

Tsui J, Qi S, Perrino S, Leibovitch M, Brodt P. Identification of a Resistance Mechanism to IGF-IR Targeting in Human Triple Negative MDA-MB-231 Breast Cancer Cells. Biomolecules. 2021;11: pubmed publisher

Morishita A, Nomura K, Tani J, Fujita K, Iwama H, Takuma K, et al. Galectin‑9 suppresses the tumor growth of colon cancer in vitro and in vivo. Oncol Rep. 2021;45: pubmed publisher

Singh N, Frey N, Engels B, Barrett D, Shestova O, Ravikumar P, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med. 2021;27:842-850 pubmed publisher

Zhang P, Liu X, Guo P, Li X, He Z, Li Z, et al. Effect of cyclic mechanical loading on immunoinflammatory microenvironment in biofabricating hydroxyapatite scaffold for bone regeneration. Bioact Mater. 2021;6:3097-3108 pubmed publisher

Royer Pokora B, Busch M, Tenbusch S, Schmidt M, Beier M, Woods A, et al. Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations. Cancers (Basel). 2020;13: pubmed publisher

H xfc ser L, Kokkaleniou M, Granados K, Dworacek J, Federico A, Vierthaler M, et al. HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma. Cancers (Basel). 2020;12: pubmed publisher

Fuentes Baile M, Ventero M, Encinar J, Garcia Morales P, Poveda Deltell M, Pérez Valenciano E, et al. Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. Cancers (Basel). 2020;12: pubmed publisher

Pietrobono S, Anichini G, Sala C, Manetti F, Almada L, Pepe S, et al. ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. Nat Commun. 2020;11:5865 pubmed publisher

Areeb Z, Stuart S, West A, Gomez J, Nguyen H, Paradiso L, et al. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Sci Rep. 2020;10:17768 pubmed publisher

Zhou B, Liu J, Zeng L, Zhu S, Wang H, Billiar T, et al. Extracellular SQSTM1 mediates bacterial septic death in mice through insulin receptor signalling. Nat Microbiol. 2020;5:1576-1587 pubmed publisher

Hollosi P, Váncza L, Karaszi K, Dobos K, Péterfia B, Tátrai E, et al. Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. Biomolecules. 2020;10: pubmed publisher

Lee E, Lee E, Yoon J, Hong A, Nam S, Ko J. Sarmentosamide, an Anti-Aging Compound from a Marine-Derived Streptomyces sp. APmarine042. Mar Drugs. 2020;18: pubmed publisher

Roy S, Laroche Clary A, Verbeke S, Derieppe M, Italiano A. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies. Cancers (Basel). 2020;12: pubmed publisher

Kim S, Cho H, Hong S, Oh S, Lee H, Cho E, et al. LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. Autophagy. 2020;:1-20 pubmed publisher

Cheng C, Yang S, Lai C, Wang C, Chang C, Lin C, et al. CXCL14 Maintains hESC Self-Renewal through Binding to IGF-1R and Activation of the IGF-1R Pathway. Cells. 2020;9: pubmed publisher

Liao W, Liao C, Tseng T, Ho Y, Chen Y, Lin K, et al. Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability. Oncogenesis. 2020;9:9 pubmed publisher

Lee P, Chen S, Kuo T, Lin T, Lin M, Huang J, et al. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer. Oncogene. 2020;39:2724-2740 pubmed publisher

Lee J, Lee J, Sim W, Kim J. Differential Dependency of Human Pancreatic Cancer Cells on Targeting PTEN via PLK 1 Expression. Cancers (Basel). 2020;12: pubmed publisher

Yanagitani N, Uchibori K, Koike S, Tsukahara M, Kitazono S, Yoshizawa T, et al. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Sci. 2020;111:932-939 pubmed publisher

Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, et al. IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Mol Cancer Res. 2020;18:549-559 pubmed publisher

Skoda J, Neradil J, Staniczkova Zambo I, Nunukova A, Macsek P, Borankova K, et al. Serial Xenotransplantation in NSG Mice Promotes a Hybrid Epithelial/Mesenchymal Gene Expression Signature and Stemness in Rhabdomyosarcoma Cells. Cancers (Basel). 2020;12: pubmed publisher

Kim J, Novak D, Sachpekidis C, Utikal J, Larribere L. STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations. Cancers (Basel). 2020;12: pubmed publisher

Kuo M, Long Y, Tsai W, Li Y, Chen H, Feun L, et al. Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors. Transl Oncol. 2020;13:355-364 pubmed publisher

MacFarland S, Naraparaju K, Iyer R, Guan P, Kolla V, Hu Y, et al. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model. Mol Cancer Ther. 2020;19:920-926 pubmed publisher

de Laat M, Spence R, Sillence M, Pollitt C. An investigation of the equine epidermal growth factor system during hyperinsulinemic laminitis. PLoS ONE. 2019;14:e0225843 pubmed publisher

Meng F, Wu L, Dong L, Mitchell A, James Block C, Liu J, et al. EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming. Nat Commun. 2019;10:5033 pubmed publisher

Zhang Q, Liu J, Liu J, Qi C, Yan L, Chen Y, et al. Activation and function of receptor tyrosine kinases in human clear cell renal cell carcinomas. BMC Cancer. 2019;19:1044 pubmed publisher

Nakai S, Yamada S, Outani H, Nakai T, Yasuda N, Mae H, et al. Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs. Sci Rep. 2019;9:15812 pubmed publisher

Sulahian R, Kwon J, Walsh K, Pailler E, Bosse T, Thaker M, et al. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Rep. 2019;29:118-134.e8 pubmed publisher

Sato T, Yoo S, Kong R, Sinha A, Chandramani Shivalingappa P, Patel A, et al. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma. Cancer Res. 2019;79:6084-6100 pubmed publisher

Lee N, Jang W, Seo J, Lee S, Jeong C. 2-Deoxy-d-Glucose-Induced Metabolic Alteration in Human Oral Squamous SCC15 Cells: Involvement of N-Glycosylation of Axl and Met. Metabolites. 2019;9: pubmed publisher

Njah K, Chakraborty S, Qiu B, Arumugam S, Raju A, Pobbati A, et al. A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis. Cell Rep. 2019;28:949-965.e7 pubmed publisher

Chen Y, Lv H, Shen N, Wang X, Tang S, Xiong B, et al. EPHA2 feedback activation limits the response to PDEδ inhibition in KRAS-dependent cancer cells. Acta Pharmacol Sin. 2019;: pubmed publisher

Horvath Z, Reszegi A, Szilak L, Dankó T, Kovalszky I, Baghy K. Tumor-specific inhibitory action of decorin on different hepatoma cell lines. Cell Signal. 2019;62:109354 pubmed publisher

Matsui T, Chiyo T, Kobara H, Fujihara S, Fujita K, Namima D, et al. Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo. Int J Mol Sci. 2019;20: pubmed publisher

Park S, Jo M, Kim B, Jeong Y, Na Y, Kim J, et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics. 2019;9:2235-2251 pubmed publisher

Xiao Z, Sperl B, Gartner S, Nedelko T, Stacher Priehse E, Ullrich A, et al. Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach. Oncotarget. 2019;10:2546-2560 pubmed publisher

Kurimchak A, Shelton C, Herrera Montávez C, Duncan K, Chernoff J, Duncan J. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. Mol Cancer Res. 2019;: pubmed publisher

Linkous A, Balamatsias D, Snuderl M, Edwards L, Miyaguchi K, MILNER T, et al. Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Rep. 2019;26:3203-3211.e5 pubmed publisher

Graves Deal R, Bogatcheva G, Rehman S, Lu Y, Higginbotham J, Singh B. Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer. Oncotarget. 2019;10:1320-1333 pubmed publisher

Rao S, Du G, Hafner M, Subramanian K, Sorger P, Gray N. A multitargeted probe-based strategy to identify signaling vulnerabilities in cancers. J Biol Chem. 2019;294:8664-8673 pubmed publisher

He L, Gao L, Shay C, Lang L, Lv F, Teng Y. Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis. J Exp Clin Cancer Res. 2019;38:84 pubmed publisher

Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, et al. Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer Res. 2019;79:1658-1670 pubmed publisher

van der Waals L, Laoukili J, Jongen J, Raats D, Borel Rinkes I, Kranenburg O. Differential anti-tumour effects of MTH1 inhibitors in patient-derived 3D colorectal cancer cultures. Sci Rep. 2019;9:819 pubmed publisher

Ahmed T, Adamopoulos C, Karoulia Z, Wu X, Sachidanandam R, Aaronson S, et al. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors. Cell Rep. 2019;26:65-78.e5 pubmed publisher

Wang X, Ai J, Liu H, Peng X, Chen H, Chen Y, et al. The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors. Mol Cancer Ther. 2019;18:667-679 pubmed publisher

Choi S, Kim A, Nam J, Kim J, Kim J, Seo H, et al. Tumour-vasculature development via endothelial-to-mesenchymal transition after radiotherapy controls CD44v6+ cancer cell and macrophage polarization. Nat Commun. 2018;9:5108 pubmed publisher

Sin S, Li Y, Liu M, Ma S, Guan X. TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling. Gynecol Oncol. 2019;152:185-193 pubmed publisher

Jang W, Jung S, Vo T, Jeong C. Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. J Cell Mol Med. 2019;23:1106-1115 pubmed publisher

Painuly U, Ramakrishnan V, Kimlinger T, Wellik L, Haug J, Gonsalves W, et al. Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget. 2018;9:34582-34594 pubmed publisher

Heliste J, Jokilammi A, Paatero I, Chakroborty D, Stark C, Savunen T, et al. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target. BMC Cardiovasc Disord. 2018;18:196 pubmed publisher

Boichuk S, Galembikova A, Dunaev P, Micheeva E, Valeeva E, Novikova M, et al. Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo. Molecules. 2018;23: pubmed publisher

Virzì A, Gentile A, Benvenuti S, Comoglio P. Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. Proc Natl Acad Sci U S A. 2018;115:10058-10063 pubmed publisher

Yángüez E, Hunziker A, Dobay M, Yildiz S, Schading S, Elshina E, et al. Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target. Nat Commun. 2018;9:3679 pubmed publisher

Sun S, Zhang Y, Zheng J, Duan B, Cui J, Chen Y, et al. HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation. Cell Death Dis. 2018;9:929 pubmed publisher

Srámek M, Neradil J, Macigova P, Mudry P, Polaskova K, Slaby O, et al. Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis. Int J Mol Sci. 2018;19: pubmed publisher

Patwardhan P, Musi E, Schwartz G. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma. Mol Cancer Ther. 2018;17:2329-2340 pubmed publisher

Chen S, Kuo T, Liao Y, Lin M, Tien Y, Huang M. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway. Oncogene. 2018;37:6041-6053 pubmed publisher

Fang Z, Jung K, Yan H, Kim S, Rumman M, Park J, et al. Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. Cell Physiol Biochem. 2018;47:1751-1768 pubmed publisher

Greenall S, Donoghue J, Johns T, Adams T. Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3. Transl Oncol. 2018;11:971-978 pubmed publisher

Donson A, Amani V, Warner E, Griesinger A, Witt D, Levy J, et al. Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther. 2018;17:1984-1994 pubmed publisher

Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, et al. YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A. 2018;115:E6030-E6038 pubmed publisher

Daneshmanesh A, Hojjat Farsangi M, Ghaderi A, Moshfegh A, Hansson L, Schultz J, et al. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. PLoS ONE. 2018;13:e0198038 pubmed publisher

Leonard B, Brand T, O Keefe R, Lee E, Zeng Y, Kemmer J, et al. BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer Res. 2018;78:4331-4343 pubmed publisher

Haas B, Klinger V, Keksel C, Bonigut V, Kiefer D, Caspers J, et al. Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int. 2018;18:69 pubmed publisher

Jung S, Lim H, Liu L, Chang J, Lim Y, Rha K, et al. LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals. Sci Rep. 2018;8:2718 pubmed publisher

Mao F, Holmlund C, Faraz M, Wang W, Bergenheim T, Kvarnbrink S, et al. Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. Oncogenesis. 2018;7:13 pubmed publisher

Ninomiya K, Ohashi K, Makimoto G, Tomida S, Higo H, Kayatani H, et al. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Sci Rep. 2018;8:1955 pubmed publisher

Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber A, et al. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene. 2018;37:1775-1787 pubmed publisher

Herr R, Halbach S, Heizmann M, Busch H, Boerries M, Brummer T. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene. 2018;37:1576-1593 pubmed publisher

Wang D, Liu C, Wang J, Jia Y, Hu X, Jiang H, et al. Protein C receptor stimulates multiple signaling pathways in breast cancer cells. J Biol Chem. 2018;293:1413-1424 pubmed publisher

Noh K, Mangala L, Han H, Zhang N, Pradeep S, Wu S, et al. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017;21:2785-2795 pubmed publisher

Chauvin C, Leruste A, Tauziède Espariat A, Andrianteranagna M, Surdez D, Lescure A, et al. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors. Cell Rep. 2017;21:1737-1745 pubmed publisher

Pearson H, Iida M, Orbuch R, McDaniel N, Nickel K, Kimple R, et al. Overcoming Resistance to Cetuximab with Honokiol, A Small-Molecule Polyphenol. Mol Cancer Ther. 2018;17:204-214 pubmed publisher

Oura K, Tadokoro T, Fujihara S, Morishita A, Chiyo T, Samukawa E, et al. Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. Oncol Rep. 2017;38:2825-2835 pubmed publisher

Adelaiye Ogala R, Budka J, Damayanti N, Arrington J, Ferris M, Hsu C, et al. EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Res. 2017;77:6651-6666 pubmed publisher

Owusu B, Thomas S, Venukadasula P, Han Z, Janetka J, Galemmo R, et al. Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget. 2017;8:63014-63025 pubmed publisher

Lyons A, Coleman M, Riis S, Favre C, O Flanagan C, Zhdanov A, et al. Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells. J Biol Chem. 2017;292:16983-16998 pubmed publisher

Klameth L, Rath B, Hamilton G. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines. J Cancer. 2017;8:1733-1743 pubmed publisher

Chen W, Kuang Y, Qiu H, Cao Z, Tu Y, Sheng Q, et al. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017;77:5107-5117 pubmed publisher

Hsu H, Lai M, Lee J, Yen M, Weng T, Chen W, et al. Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling. Sci Rep. 2017;7:5823 pubmed publisher

Aarnio Peterson M, Zhao P, Yu S, Christian C, Flanagan Steet H, Wells L, et al. Altered Met receptor phosphorylation and LRP1-mediated uptake in cells lacking carbohydrate-dependent lysosomal targeting. J Biol Chem. 2017;292:15094-15104 pubmed publisher

Mansouri R, Jouan Y, Hay E, Blin Wakkach C, Frain M, Ostertag A, et al. Osteoblastic heparan sulfate glycosaminoglycans control bone remodeling by regulating Wnt signaling and the crosstalk between bone surface and marrow cells. Cell Death Dis. 2017;8:e2902 pubmed publisher

Miyata K, Takemoto A, Okumura S, Nishio M, Fujita N. Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Sci Rep. 2017;7:4059 pubmed publisher

Malchers F, Ercanoglu M, Schütte D, Castiglione R, Tischler V, Michels S, et al. Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. Clin Cancer Res. 2017;23:5527-5536 pubmed publisher

Lampada A, O Prey J, Szabadkai G, Ryan K, Hochhauser D, Salomoni P. mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism. Cell Death Differ. 2017;24:1045-1062 pubmed publisher

Jin H, Park J, Kim H, Chang Y, Hong Y, Park I, et al. Piperlongumine downregulates the expression of HER family in breast cancer cells. Biochem Biophys Res Commun. 2017;486:1083-1089 pubmed publisher

Xu L, Chen Y, Dutra Clarke M, Mayakonda A, Hazawa M, Savinoff S, et al. BCL6 promotes glioma and serves as a therapeutic target. Proc Natl Acad Sci U S A. 2017;114:3981-3986 pubmed publisher

Yadav S, Li J, Stockert J, Herzog B, O CONNOR J, Garzon Manco L, et al. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Transl Oncol. 2017;10:357-366 pubmed publisher

Li C, Singh B, Graves Deal R, Ma H, Starchenko A, Fry W, et al. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer. Proc Natl Acad Sci U S A. 2017;114:E2852-E2861 pubmed publisher

Buchanan P, Boylan K, Walcheck B, Heinze R, Geller M, Argenta P, et al. Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17. J Biol Chem. 2017;292:6339-6351 pubmed publisher

Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, et al. Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Res. 2017;77:2078-2089 pubmed publisher

Saintas E, Abrahams L, Ahmad G, Ajakaiye A, AlHumaidi A, Ashmore Harris C, et al. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS. PLoS ONE. 2017;12:e0172140 pubmed publisher

Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, et al. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Mol Cancer Ther. 2017;16:506-515 pubmed publisher

Neill T, Buraschi S, Goyal A, Sharpe C, Natkanski E, Schaefer L, et al. EphA2 is a functional receptor for the growth factor progranulin. J Cell Biol. 2016;215:687-703 pubmed

Ciaglia E, Abate M, Laezza C, Pisanti S, Vitale M, Seneca V, et al. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor. Int J Cancer. 2017;140:959-972 pubmed publisher

Xu Y, Wang K, Yu Q. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases. Oncotarget. 2016;7:70080-70091 pubmed publisher

Cassinelli G, Favini E, Dal Bo L, Tortoreto M, De Maglie M, Dagrada G, et al. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget. 2016;7:47848-47863 pubmed publisher

Aghajanian H, Cho Y, Manderfield L, Herling M, Gupta M, Ho V, et al. Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor. Nat Commun. 2016;7:12038 pubmed publisher

Brandt A, Löhers K, Beier M, Leube B, de Torres C, Mora J, et al. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. PLoS ONE. 2016;11:e0155561 pubmed publisher

Huang M, Liu T, Ma P, Mitteer R, Zhang Z, Kim H, et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J Clin Invest. 2016;126:1801-14 pubmed publisher

Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed publisher

Yamaguchi T, Lu C, Ida L, Yanagisawa K, Usukura J, Cheng J, et al. ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1. Nat Commun. 2016;7:10060 pubmed publisher

Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, et al. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Mol Cancer Ther. 2016;15:162-71 pubmed publisher

Szymańska E, Skowronek A, Miaczynska M. Impaired dynamin 2 function leads to increased AP-1 transcriptional activity through the JNK/c-Jun pathway. Cell Signal. 2016;28:160-71 pubmed publisher

Heim E, Marston J, Federman R, Edwards A, Karabadzhak A, Petti L, et al. Biologically active LIL proteins built with minimal chemical diversity. Proc Natl Acad Sci U S A. 2015;112:E4717-25 pubmed publisher

Chung S, Dwabe S, Elshimali Y, Sukhija H, Aroh C, Vadgama J. Identification of Novel Biomarkers for Metastatic Colorectal Cancer Using Angiogenesis-Antibody Array and Intracellular Signaling Array. PLoS ONE. 2015;10:e0134948 pubmed publisher

Broecker Preuss M, Müller S, Britten M, Worm K, Schmid K, Mann K, et al. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC Cancer. 2015;15:184 pubmed publisher

Cohen N, Zeng S, Seifert A, Kim T, Sorenson E, Greer J, et al. Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Res. 2015;75:2061-70 pubmed publisher

Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw C, Miao B, et al. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015;135:1863-1872 pubmed publisher

Ito K, Sakai K, Suzuki Y, Ozawa N, Hatta T, Natsume T, et al. Artificial human Met agonists based on macrocycle scaffolds. Nat Commun. 2015;6:6373 pubmed publisher

Laukkanen M, Cammarota F, Esposito T, Salvatore M, Castellone M. Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI. PLoS ONE. 2015;10:e0121441 pubmed publisher

Song A, Kim T, Kim D, Kim S, Keam B, Lee S, et al. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res. 2015;21:2379-87 pubmed publisher

Wu J, Hu C, You R, Ma P, Pan S, Lee M, et al. Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways. PLoS ONE. 2015;10:e0114495 pubmed publisher

Tworkoski K, Raab Traub N. LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation. J Virol. 2015;89:2590-602 pubmed publisher

Zemskova M, Song J, Cen B, Cerda Infante J, Montecinos V, Kraft A. Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal. 2015;27:135-46 pubmed publisher

Puzanov I, Lindsay C, Goff L, Sosman J, Gilbert J, Berlin J, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res. 2015;21:701-11 pubmed publisher

Imura Y, Yasui H, Outani H, Wakamatsu T, Hamada K, Nakai T, et al. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma. Mol Cancer. 2014;13:185 pubmed publisher

Shiono M, Kobayashi T, Takahashi R, Ueda M, Ishioka C, Hino O. Transgenic expression of the N525S-tuberin variant in Tsc2 mutant (Eker) rats causes dominant embryonic lethality. Sci Rep. 2014;4:5927 pubmed publisher

Outani H, Tanaka T, Wakamatsu T, Imura Y, Hamada K, Araki N, et al. Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS. BMC Cancer. 2014;14:455 pubmed publisher

Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher

Wang L, Hsiao T, Hong T, Chen H, Kao S, Wang W, et al. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS ONE. 2014;9:e96765 pubmed publisher

Cuenca Lopez M, Montero J, Morales J, Prat A, Pandiella A, Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 2014;14:302 pubmed publisher

Calero R, Morchon E, Johnsen J, Serrano R. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis. PLoS ONE. 2014;9:e95628 pubmed publisher

Miyagawa Yamaguchi A, Kotani N, Honke K. Expressed glycosylphosphatidylinositol-anchored horseradish peroxidase identifies co-clustering molecules in individual lipid raft domains. PLoS ONE. 2014;9:e93054 pubmed publisher

Song W, Ma Y, Wang J, Brantley Sieders D, Chen J. JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer. Cancer Res. 2014;74:2444-54 pubmed publisher

Banerjee J, Das Ghatak P, Roy S, Khanna S, Sequin E, Bellman K, et al. Improvement of human keratinocyte migration by a redox active bioelectric dressing. PLoS ONE. 2014;9:e89239 pubmed publisher

Camorani S, Esposito C, Rienzo A, Catuogno S, Iaboni M, Condorelli G, et al. Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFR? aptamer. Mol Ther. 2014;22:828-41 pubmed publisher

Sakanyan V, Angelini M, Le Béchec M, Lecocq M, Benaiteau F, Rousseau B, et al. Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells. Sci Rep. 2014;4:3977 pubmed publisher

Carlino M, Todd J, Gowrishankar K, Mijatov B, Pupo G, Fung C, et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol Oncol. 2014;8:544-54 pubmed publisher

Lekawanvijit S, Kumfu S, Wang B, Manabe M, Nishijima F, Kelly D, et al. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction. PLoS ONE. 2013;8:e83687 pubmed publisher

Davies K, Mahale S, Astling D, Aisner D, Le A, Hinz T, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS ONE. 2013;8:e82236 pubmed publisher

Okon I, Coughlan K, Zou M. Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells. J Biol Chem. 2014;289:1639-48 pubmed publisher

de Freitas Junior J, Carvalho S, Dias A, Oliveira P, Cabral J, Seruca R, et al. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. an interplay with E-cadherin. PLoS ONE. 2013;8:e81579 pubmed publisher

Skoda J, Neradil J, Zitterbart K, Sterba J, Veselska R. EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy. Oncol Rep. 2014;31:480-7 pubmed publisher

Drake J, Graham N, Lee J, Stoyanova T, Faltermeier C, Sud S, et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013;110:E4762-9 pubmed publisher

Son M, Seol B, Han Y, Cho Y. Comparative receptor tyrosine kinase profiling identifies a novel role for AXL in human stem cell pluripotency. Hum Mol Genet. 2014;23:1802-16 pubmed publisher

Lei H, Kazlauskas A. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor ?. Mol Cell Biol. 2014;34:110-22 pubmed publisher

Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pföhler C, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res. 2014;20:499-510 pubmed publisher

Li L, Chakraborty S, Yang C, Hatanpaa K, Cipher D, Puliyappadamba V, et al. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. Oncogene. 2014;33:4253-64 pubmed publisher

Kwon H, Johnson T, Joe M, Abu Asab M, Zhang J, Chan C, et al. Myocilin mediates myelination in the peripheral nervous system through ErbB2/3 signaling. J Biol Chem. 2013;288:26357-71 pubmed publisher

Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, et al. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene. 2014;33:1850-61 pubmed publisher

Krzyzaniak M, Zumstein M, Gerez J, Picotti P, Helenius A. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 2013;9:e1003309 pubmed publisher

Britschgi A, Bill A, Brinkhaus H, Rothwell C, Clay I, Duss S, et al. Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling. Proc Natl Acad Sci U S A. 2013;110:E1026-34 pubmed publisher

Lee H, Bennett A. Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration. Mol Cell Biol. 2013;33:1430-41 pubmed publisher

Montero J, Esparis Ogando A, Re Louhau M, Seoane S, Abad M, Calero R, et al. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene. 2014;33:148-56 pubmed publisher

Lin S, Lee Y, Wang J, Miller S, Chiou S, Hung M, et al. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PLoS ONE. 2012;7:e49605 pubmed publisher

Joshi A, Loilome W, Siu I, Tyler B, Gallia G, Riggins G. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy. PLoS ONE. 2012;7:e44372 pubmed publisher

Purushothaman A, Babitz S, Sanderson R. Heparanase enhances the insulin receptor signaling pathway to activate extracellular signal-regulated kinase in multiple myeloma. J Biol Chem. 2012;287:41288-96 pubmed publisher

Kotani N, Ishiura Y, Yamashita R, Ohnishi T, Honke K. Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells. J Biol Chem. 2012;287:37109-18 pubmed publisher

Davies K, Le A, Theodoro M, Skokan M, Aisner D, Berge E, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18:4570-9 pubmed publisher

Ganesh K, Das A, Dickerson R, Khanna S, Parinandi N, Gordillo G, et al. Prostaglandin E? induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. J Immunol. 2012;189:2563-73 pubmed publisher

Ho A, Vasudeva S, Lae M, Saito T, Barbashina V, Antonescu C, et al. PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma. Cancer Res. 2012;72:4515-25 pubmed publisher

Duncan J, Whittle M, Nakamura K, Abell A, Midland A, Zawistowski J, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149:307-21 pubmed publisher

Oliveras Ferraros C, Cufí S, Queralt B, Vazquez Martin A, Martin Castillo B, de Llorens R, et al. Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. Br J Cancer. 2012;106:1406-14 pubmed publisher

Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, et al. Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res. 2012;72:2501-11 pubmed publisher

Gowrishankar K, Snoyman S, Pupo G, Becker T, Kefford R, Rizos H. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol. 2012;132:1850-9 pubmed publisher

Ball S, Shuttleworth A, Kielty C. Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cells. 2012;30:548-60 pubmed publisher

Poulikakos P, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387-90 pubmed publisher

Lorenzon E, Colladel R, Andreuzzi E, Marastoni S, Todaro F, Schiappacassi M, et al. MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene. 2012;31:3136-47 pubmed publisher

Tang W, Stitham J, Gleim S, Di Febbo C, Porreca E, Fava C, et al. Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest. 2011;121:4462-76 pubmed publisher

Jiao Y, Ou W, Meng F, Zhou H, Wang A. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer. 2011;10:125 pubmed publisher

Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer. 2011;105:807-13 pubmed publisher

Lupberger J, Zeisel M, Xiao F, Thumann C, Fofana I, Zona L, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med. 2011;17:589-95 pubmed publisher

Tanabe H, Kuribayashi K, Tsuji N, Tanaka M, Kobayashi D, Watanabe N. Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2. Int J Oncol. 2011;39:33-40 pubmed publisher

Karki R, Lang S, Means R. The MARCH family E3 ubiquitin ligase K5 alters monocyte metabolism and proliferation through receptor tyrosine kinase modulation. PLoS Pathog. 2011;7:e1001331 pubmed publisher

Carrasco Garcia E, Saceda M, Grasso S, Rocamora Reverte L, Conde M, Gómez Martínez A, et al. Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res. 2011;317:1476-89 pubmed publisher

Ding V, Boersema P, Foong L, Preisinger C, Koh G, Natarajan S, et al. Tyrosine phosphorylation profiling in FGF-2 stimulated human embryonic stem cells. PLoS ONE. 2011;6:e17538 pubmed publisher

Chakrabarty A, Sanchez V, Kuba M, Rinehart C, Arteaga C. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci U S A. 2012;109:2718-23 pubmed publisher

Henriksson M, Edin S, Dahlin A, Oldenborg P, Oberg A, Van Guelpen B, et al. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion. Am J Pathol. 2011;178:1387-94 pubmed publisher

McKinley E, Bugaj J, Zhao P, Guleryuz S, Mantis C, Gokhale P, et al. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin Cancer Res. 2011;17:3332-40 pubmed publisher

Ou W, Hubert C, Corson J, Bueno R, Flynn D, Sugarbaker D, et al. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma. Neoplasia. 2011;13:12-22 pubmed

Villanueva J, Vultur A, Lee J, Somasundaram R, Fukunaga Kalabis M, Cipolla A, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-95 pubmed publisher

Godshalk S, Paranjape T, Nallur S, Speed W, Chan E, Molinaro A, et al. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene. 2011;30:1542-50 pubmed publisher

Nazarian R, Shi H, Wang Q, Kong X, Koya R, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973-7 pubmed publisher

Csepeggi C, Jiang M, Kojima F, Crofford L, Frolov A. Somatic cell plasticity and Niemann-Pick type C2 protein: fibroblast activation. J Biol Chem. 2011;286:2078-87 pubmed publisher

Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 2010;16:5489-98 pubmed publisher

Flanigan S, Pitts T, Eckhardt S, Tentler J, Tan A, Thorburn A, et al. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Clin Cancer Res. 2010;16:5436-46 pubmed publisher

Dewaele B, Floris G, Finalet Ferreiro J, Fletcher C, Coindre J, Guillou L, et al. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res. 2010;70:7304-14 pubmed publisher

Oliveras Ferraros C, Vazquez Martin A, Martin Castillo B, Pérez Martínez M, Cufí S, del Barco S, et al. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol. 2010;37:669-78 pubmed

Csepeggi C, Jiang M, Frolov A. Somatic cell plasticity and Niemann-pick type C2 protein: adipocyte differentiation and function. J Biol Chem. 2010;285:30347-54 pubmed publisher

Ding W, Knox T, Tschumper R, Wu W, Schwager S, Boysen J, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116:2984-93 pubmed publisher

Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou Strauss A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer. 2010;103:196-200 pubmed publisher

Negri T, Virdis E, Brich S, Bozzi F, Tamborini E, Tarantino E, et al. Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin Cancer Res. 2010;16:3581-93 pubmed publisher

Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9:1286-97 pubmed publisher

Kang H, Jenabi J, Liu X, Reynolds C, Triche T, Sorensen P. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther. 2010;9:1396-407 pubmed publisher

Roorda B, ter Elst A, Scherpen F, Meeuwsen de Boer T, Kamps W, de Bont E. VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27(KIP1) via paracrine mechanisms. Eur J Cancer. 2010;46:974-82 pubmed publisher

Franovic A, Holterman C, Payette J, Lee S. Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A. 2009;106:21306-11 pubmed publisher

Cook S, Varela Carver A, Mongillo M, Kleinert C, Khan M, Leccisotti L, et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur Heart J. 2010;31:100-11 pubmed publisher

Yoon Y, Kim H, Han S, Hur H, Oh D, Im S, et al. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther. 2009;8:2526-36 pubmed publisher

Bax D, Gaspar N, Little S, Marshall L, Perryman L, Regairaz M, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res. 2009;15:5753-61 pubmed publisher

Eiselleova L, Matulka K, Kriz V, Kunova M, Schmidtova Z, Neradil J, et al. A complex role for FGF-2 in self-renewal, survival, and adhesion of human embryonic stem cells. Stem Cells. 2009;27:1847-57 pubmed publisher

Goldoni S, Humphries A, Nyström A, Sattar S, Owens R, McQuillan D, et al. Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol. 2009;185:743-54 pubmed publisher

Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis. 2009;30:1097-105 pubmed publisher

Eckstein N, Servan K, Hildebrandt B, Pölitz A, von Jonquieres G, Wolf Kümmeth S, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009;69:2996-3003 pubmed publisher

Kobayashi T, Furukawa Y, Kikuchi J, Ito C, Miyata Y, Muto S, et al. Transactivation of RON receptor tyrosine kinase by interaction with PDGF receptor beta during steady-state growth of human mesangial cells. Kidney Int. 2009;75:1173-1183 pubmed publisher

Agarwal S, Zerillo C, Kolmakova J, Christensen J, Harris L, Rimm D, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells. Br J Cancer. 2009;100:941-9 pubmed publisher

Kashiwagi K, Virgona N, Harada K, Kido W, Yano Y, Ando A, et al. A redox-silent analogue of tocotrienol acts as a potential cytotoxic agent against human mesothelioma cells. Life Sci. 2009;84:650-6 pubmed publisher

Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota S, Orsenigo M, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15:1096-104 pubmed publisher

Marston E, Weston V, Jesson J, Maina E, McConville C, Agathanggelou A, et al. Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response. Blood. 2009;113:117-26 pubmed publisher

Buck E, Eyzaguirre A, Rosenfeld Franklin M, Thomson S, Mulvihill M, Barr S, et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008;68:8322-32 pubmed publisher

Shimamura T, Li D, Ji H, Haringsma H, Liniker E, Borgman C, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008;68:5827-38 pubmed publisher

Koivunen J, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes A, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275-83 pubmed publisher

Agaram N, Laquaglia M, Ustun B, Guo T, Wong G, Socci N, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008;14:3204-15 pubmed publisher

Mueller K, Hunter L, Ethier S, Boerner J. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008;68:3314-22 pubmed publisher

Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008;68:2340-8 pubmed publisher

Yu L, Saile K, Swartz C, He H, Zheng X, Kissling G, et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med. 2008;14:264-75 pubmed publisher

Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, et al. Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem. 2008;283:739-50 pubmed

Stommel J, Kimmelman A, Ying H, Nabioullin R, Ponugoti A, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287-90 pubmed

Wang L, Schulz T, Sherrer E, Dauphin D, Shin S, Nelson A, et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood. 2007;110:4111-9 pubmed

Lomas A, Mellody K, Freeman L, Bax D, Shuttleworth C, Kielty C. Fibulin-5 binds human smooth-muscle cells through alpha5beta1 and alpha4beta1 integrins, but does not support receptor activation. Biochem J. 2007;405:417-28 pubmed

Ball S, Shuttleworth C, Kielty C. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol. 2007;177:489-500 pubmed

Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039-43 pubmed

Kang H, Jenabi J, Zhang J, Keshelava N, Shimada H, May W, et al. E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase. Cancer Res. 2007;67:3094-105 pubmed

Fujikawa T, Shiraha H, Ueda N, Takaoka N, Nakanishi Y, Matsuo N, et al. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J Biol Chem. 2007;282:8741-8 pubmed

Menendez J, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol. 2006;24:3735-46 pubmed

Cohen E, Lingen M, Zhu B, Zhu H, Straza M, Pierce C, et al. Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase. Cancer Res. 2006;66:6296-303 pubmed